Novelty Technology Care Espana (Part of GRUPO NTC) Listed by genesis Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

Ransomware operations targeting European healthcare and pharmaceutical entities remain a persistent feature of the threat landscape. On January 11, 2026, the genesis ransomware group listed Novelty Technology Care Espana, a Spanish pharmaceutical company operating as part of GRUPO NTC, on its data-leak site. The listing asserts that internal files were exfiltrated during a ransomware attack. Public information on the number of individuals affected or the precise volume of data remains unavailable.

Inside the incident

The available facts are limited to the group’s public listing of the company. No independent confirmation of the claimed exfiltration has been reported, nor have details on the attack timeline, encryption methods, or ransom demands been disclosed. The organization is described only as a pharmaceutical company based in Spain. Scale indicators, such as the number of files or affected records, are not provided in the listing.

Inside genesis

Genesis operates as a ransomware group that maintains a leak site to publish data allegedly obtained from victims. Like other actors in this category, it employs a double-extortion model in which data is first copied and later threatened with public release if payment demands are not met. Public records document similar activity by the group against organizations in multiple countries and sectors, though each listing constitutes an unverified claim by the group itself.

Who is GRUPO NTC?

GRUPO NTC encompasses pharmaceutical operations in Spain, including Novelty Technology Care Espana. Companies in this sector routinely manage research records, manufacturing documentation, regulatory submissions, and supply-chain information. A breach affecting such an entity can intersect with both commercial operations and regulatory obligations under European data-protection frameworks.

The information in question

The listing states that internal files were exfiltrated. No further breakdown of file categories or data fields has been released. Organizations of this type commonly hold formulation data, clinical-trial documentation, employee records, and partner agreements; however, the exact contents of any exfiltrated material remain unconfirmed beyond the general description provided in the claim.

Why it matters

Exposure of internal pharmaceutical files can create operational and regulatory complications for the affected company. For individuals whose information appears in such files, potential consequences include misuse of personal or professional details already held by the organization. The absence of confirmed data volumes leaves the scope of any downstream risk undetermined at present.

If your data was in this claimed breach

Individuals concerned about possible exposure should monitor official communications from GRUPO NTC or its subsidiaries. Practical first steps include reviewing account statements for unusual activity, enabling multi-factor authentication on any services that may hold related information, and maintaining current backups of personal records. Readers can also run a free exposure scan of their email address against known breach data sets to check for appearances in previously published incidents.

AICompiled with AI assistance from public sources and published under our editorial standards.